Public Company News

Following several recent divestments, Aurumin has made good its promise to home in on its 946,000-ounce Sandstone gold project in Western Australia’s Mid West region after revealing it had secured three new exploration licences. The move more than doubles the company’s presence in the central project area as it gets closer to eradicating an overhanging $6.4 million debt relating to its Sandstone acquisition last year.

American West Metals has confirmed outstanding grades of 38.2 per cent copper and 30.87 per cent zinc from geochemical sampling at the Tempest prospect that forms part of its greater Storm project in Canada. The results came from surface gossan rocks at the underexplored site, which have been mapped for more than 4km and are about 40km south of copper targets drilled earlier this year.

This week’s Bulls N’ Bears profiled ASX runner is… Chariot Corporation. Its shares doubled this week to join movers including Pure Resources, Sunshine Metals and Roots Sustainable Agricultural Technologies.

Aurumin has continued to level its exploration and financial focus further on its Sandstone gold project in Western Australia after selling the iron ore rights at its Mt Dimer operation to a subsidiary of Mineral Resources. It will retain exposure through progress and royalty payments as part of a $250,000 sale to Polaris Metals for iron ore rights at four of its Mt Dimer tenements.

Strickland Metals has emerged as one of the ASX’s runners of the year, jumping 400 per cent to an 11-year high of 20 cents on Thursday, on the back of more drilling at its Marwari gold prospect near Wiluna in WA. Led by entrepreneurial boss Andrew Bray, Stickland sits as the lone gold explorer among a sea of lithium hopefuls leading this year’s ASX charge.

Chimeric Therapeutics’ mission to beat cancer with its “natural killer” therapy has hit a new high point, with test-tube studies showing a 300 per cent increase in its ability to kill the pancreatic form of the insidious disease. The company’s latest revelations also show its off-the-shelf “CLTX CAR NK” cell therapy recording a 260 per cent jump in killing ovarian cancer.

Software provider K2fly has initiated a sweeping strategic review of its operations in a swift boardroom move designed to maximise the full potential of its innovative resource governance software solutions. After posting 13 quarters of increasing revenue on the trot, K2Fly has vowed not to sit on those laurels and has appointed Argonaut PCF and Atrico as joint advisors to steer its review.

Infinity Mining’s recent drilling in a big swarm of stacked Pilbara pegmatites has yielded assays of up to 2.1 per cent lithium oxide and supportive rubidium, caesium and tantalum values, with more work to come. The company says its campaign of eight reverse-circulation drillholes for 834m at its Tambourah South project in Western Australia produced several outstanding shallow lithium-caesium-tantalum intercepts.

Askari Metals has jagged a high of 24.5g/t gold in one rock-chip sample from its Myrnas Hill project in Western Australia’s East Pilbara region, while soil samples yielded up to 2g/t, 1.37g/t and other lower gold and nickel spikes. The company says the campaign also recorded elevated nickel responses of up to 1280 parts per million.

ASX-listed Gold Mountain has identified a series of lithium anomalies from stream-sediment sampling at its Logradouro project in Brazil, where the company has mapped 250 pegmatites across its two-tenement site. Management says the sampling results indicate the presence of lithium-caesium-tantalum pegmatites within the operation, with soil sampling set to follow up on selected anomalies to define drill targets.

Gold Mountain is aiming to more than double the size of its Green River copper-gold project in Papua New Guinea after lodging an application for a 552sq-km tenement adjacent to a previous 501sq-km application. Management says high-grade copper-gold and lead-zinc rock-chip samples have been found in the tenements by previous explorers, with target areas for follow-up exploration already identified.

A research and development tax rebate of nearly $5 million from the Australian Government will boost Radiopharm Theranostics’ mission to further develop its suite of diagnostic and therapeutic products aimed at beating the cancer scourge. The refund recognises the company’s R&D activity during the 2023 financial year and comes as it prepares to run clinical pancreatic cancer trials in New York.